Press release 📈 Stocks 🌍 United States ISIN US5324571083

Eli Lilly Orforglipron Outperforms Novo Nordisk Semaglutide in Clinical Data

Eli Lilly's orforglipron outperforms Novo Nordisk's oral semaglutide in recent clinical trials, showing superior weight loss and A1C reduction metrics that could shift market share in the GLP-1 space.

📅 September 29, 2026 🕐 1 min read

2 assets impacted (Stocks). Net bias: 1 Bullish, 1 Bearish, 0 Neutral. Strongest signal: LLY ↑ 7/10 (60% confidence).

📊 Affected Assets (2)

LLY

Bullish 🤖 60%

📅 Short-term 🌍 US · Explicit

Positive clinical data showing superior efficacy for orforglipron versus oral semaglutide supports Lilly's competitive position in the GLP-1 market.

NVO

Bearish 🤖 60%

📅 Short-term 🌍 DK · Explicit

Head-to-head comparison shows oral semaglutide underperforms Lilly's orforglipron on weight loss and A1C reduction, potentially pressuring Novo Nordisk's market share.

🎯 Key Takeaways

Orforglipron 17.2 mg achieved 1.5% greater weight loss than oral semaglutide 25 mg at 52 weeks.
Clinical data indicates a 0.3% greater A1C reduction for Lilly's candidate compared to Novo Nordisk's offering.
The findings from the ACHIEVE-3 study reinforce Eli Lilly's competitive advantage in the oral GLP-1 segment.

📝 Executive Summary

Eli Lilly's orforglipron demonstrated superior efficacy in a head-to-head analysis against Novo Nordisk's oral semaglutide. Data from the ACHIEVE-3 study shows orforglipron delivered 1.5% greater weight loss and 0.3% higher A1C reduction at the 52-week mark, strengthening Lilly's competitive standing in the GLP-1 market.

❓ FAQ

How does orforglipron compare to oral semaglutide?

According to the ACHIEVE-3 study, orforglipron demonstrated superior efficacy in both weight loss and A1C reduction compared to oral semaglutide over a 52-week period.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article